Review of the therapeutic effects of the traditional Chinese medicine yuye decoction on diabetes mellitus and its complications

Jack Hei Wan1*, Kar-Ho Lam1, Tian-He Song1, Xiang Lin1, Leanne Lee Leung1, Tung-Leong Fong1, Ngai Chung Lau1, Chi-Ho Wong1, Ying-Yi Huang1, George Pak-Heng Leung1, Yi-Gang Shi1, Calvin Kai-Fai Lee1, Hung Wan1, Tzi Bun Ng1, Jian-Feng Wang6, Zhang-Jin Zhang5, Kalin Yan-Bo Zhang1* and Sydney Chi-Wai Tang7*

1School of Chinese Medicine, The University of Hong Kong, 10 Sassoon Road, Hong Kong
2Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Hong Kong
3Department of Obstetrics and Gynecology, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Hong Kong
4School of Nursing, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Hong Kong
5School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
6Shanghai Anda Hospital, Department of Internal Medicine, Pudong, Shanghai, 468 South Hunan Road;
7Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, 102 Pokfulam Road, Hong Kong

Abstract

Ethnopharmacological relevance: Diabetes is a serious metabolic disease which imposes a heavy burden on the society. It may also bring about a variety of complications if the blood glucose level is not well controlled. Yuye Decoction (YYD) is an ancient herbal medicinal formulation of China and has been widely used in Traditional Chinese medicine to treat patients with diabetes for thousands of years. There are seven medicinal herbs in YYD.

Aim of the study: The aim of the present review is to summarize and critically appraise data concerning medicinal plants used in YYD, its main active constituents and signaling pathways mediating its therapeutic effects on diabetes and diabetic complications.

Materials and methods: The search of papers published in the period 2009 to 2019 and recorded in PubMed was conducted using specific search terms.

Results: After screening, 88 studies were included. Among seven medicinal herbs in YYD formulation, six of them exhibited therapeutic effects on diabetes and its complications through different signaling pathways. Most (55.7%) of the studies were animal studies. Type 2 diabetes was studied in most (37.5%) of the research papers and diabetic nephropathy was the most (19.3%) studied diabetic complication. Focus was placed on Astragalus membranaceus (Fisch.) Bge. and Pueraria lobata (Willd.) Obw in the largest number of research papers.

Conclusion: YYD exerted a therapeutic effect on diabetes and a preventive effect on diabetic complications.

Abbreviations: ACC: Acetyl CoA Carboxylase; pNF-kB: Activated Phosphorylated Derivative; Acrp30: Adiponectin; (ATP)-binding: Adenosine Triphosphate; AGEs: Advanced Glycation End Products; UA1b: Albuminuria; PGC-1α: Alpha Subunit of Peroxisome Proliferators-Activated Receptor-Gamma Coactivator-1; AMPK: AMP-Activated Protein Kinase; Arg-1: arginase-1; APS: Astragalus Proliferators-Activated Receptor-Gamma Coactivator-1; ABCB11: ATP-binding cassette (transporter) B11; Bas: bile acids; BBB: Blood-Brain Barrier; BUN: blood urea nitrogen; BW: Body Weight; CAT: catalase; JNK: Jun N-terminal kinases; Col IV: Collagen Type IV; CrCl: Creatinine Clearance; DCs: Dendritic Cells; DCM: Diabetic cardiomyopathy; DCl: Diabetic Cognitive Impairment; DPN: Diabetic Peripheral Neuropathy; DM: Diabetes (not specific); DN: Diabetic Nephropathy; DO: Diabetic Ophthalmopathy; DR: Diabetic Retinopathy; DVC: Diabetic Vascular Complications; EBPs: Enhancer Binding Protein; eNOS: Endothelial NOS; Endothelial Nitric Oxide Synthase; ESRD: End Stage Renal Disease; FBG: Fasting Blood Glucose; FABP: Fatty Acid Binding Protein; F/B ratio: Firmicutes to Bacteroidetes Ratio; FN: Fibronectin; FOXO1: Forkhead Box Protein O1; GIN: glutamine; GSH: Glutathione; GIR: Glucose Infusion Rate; GLUT2: Glucose Transporter 2; GLUT4: Glucose Transporter 4; GSH: Glutathione; GPx: Glutathione Peroxidase; HbA1C: Hemoglobin; HGF: Hepatocyte Growth Factor; HMGB1: High Mobility Group Box 1; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance; HUVECs: Human Umbilical Vein Endothelial

*Correspondence to: Kalin Y.B. Zhang, School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Hong Kong, E-mail: ybzhang@hku.hk
Jack Hei Wan, School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Hong Kong, E-mail: jack_wan88@hotmail.com
Sydney Chi-Wai TANG, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, E-mail: scwttang@hku.hk

Key words: traditional chinese medicine, diabetes, phytochemical, mechanism, medicinal plants

Received: May 09, 2020; Accepted: May 26, 2020; Published: May 29, 2020
Cells; HAT: hydroxyacetone; H2O2: Hydrogen Peroxide; IKKβ: IκB kinase β; NOxs: Inducible Nitric Oxide Synthase; IGF: Insulin-like Growth Factor-1; IRS: Insulin Receptor Substrate (IRS); IL-1β: Interleukin-1β; IL-6: Interleukin-6; IL-10: Interleukin-10; IRS: Insulin Resistance; IRS-1: Insulin Receptor Substrate-1; Ile: Isoleucine; MDA: Malondialdehyde; MnSOD: Manganese Superoxide Dismutase; MEKC: Micellar Electrokinetic Chromatography; MetS: Prediabetes & Metabolic Syndrome; mVMECs: Mouse Vascular Endothelial Cell; NO: nitric oxide; NF-κB: Nuclear-Factor Kappaβ; 2-NBDG: 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl) Amino)-2-Deoxyglucose; PPARα: Peroxisome Proliferators-Activated Receptor α; pIκB: Phospho-Insulin Receptor; P38K: Phosphatidylinositol 3-kinase; NPCs: Primary Mouse Nonparenchymal Cells; PPAR: Proliferator-Activated Receptor γ; PCNA: Proliferating Cell Nuclear Antigen; PUE: Puerarin; ROS: Reactive Oxygen Species; Tregs: Regulatory T cells; sCt: Serum Creatinine; FPG: Serum Fasting Plasma Glucose; SUA: Serum Uric Acid; SIRT1: Silent Information Regulator 1; sICAM-1: Soluble Intercellular Cell Adhesion Molecule-1; SOD: Superoxide Dismutase; STZ: streptozotocin; TXNIP: Thioredoxin-Interacting Protein; TG: Triglyceride; TC: Total Cholesterol; TNF-α: Tumor Necrosis Factor-α; T1DM: Type 1 Diabetes; T2DM: Type 2 diabetes; UAE: Urinary Albumin Excretion; ACR: Urinary Albumin/Creatinine Ratio; UDP: Uridine Diphosphate; s-VCAM-1: vascular cell adhesion molecule-1; VEGF: Vascular endothelial growth factor; VAT: visceral adipose tissue.

Introduction

Diabetes is a group of metabolic diseases characterized by hyperglycemia due to insulin resistance, absolute insulin deficiency and/or abnormal insulin secretion [1]. According to the WHO, more than 171 million people worldwide suffer from diabetes and the number of diabetic patients keeps escalating [2].

Diabetes may lead to a series of complications such as blindness, stroke, renal failure, nerve damage and limb amputation [3]. Persistent hyperglycemia brings about chronic damage to various tissues in the heart, eyes, kidneys and blood vessels and causes dysfunctions of these organs. These complications, including nephropathy, retinopathy, neuropathy, cardiomyopathy and cognitive impairment, are major causes of morbidity and mortality in diabetic patients. Consequently, diabetes has become a serious social health problem [4]. According to WHO, diabetes is expected to become the 7th leading cause of death in 2030 globally [5].

However, the current treatment of diabetes with western medicine still leaves much to be desired. There is a paucity of information available on effective treatment options for diabetic patients. Thus, the perspective of achieving good long-term metabolic control in diabetes is of central importance.6 Traditional Chinese medicine has a long history in treating diabetes and is widely popular in China. Many hospitals in China use traditional medicinal plants or a combination of western medicine with Chinese medicine to treat diabetes.

Yuye Decoction (YYD) is an ancient formulation and was first recorded in the book of Chinese medicine “yxue zhongzhong canxi lu (醫學衷中參西 註)” written by Zhang XiChun in 1909. It is widely used in Traditional Chinese medicine to treat diabetes. There are seven medicinal herbs that compose YYD, including Dioscorea opposite Thunb. (RD), Astragalus membranaceus (Fisch.) Bge. (AM), Anemarrhena asphodeloides Bge. (RA), Schisandra chinensis (Turcz.) Baill. (SCF), Trichosanthes kirilowii Maxim. (TK), Gallus gallus domesticus Brisson (GGD), and Pueraria lobata (Willd.) Ohwi (PL) (Table 1). In traditional Chinese medicine theory, YYD is beneficial to kidney function and improves the amount of body fluid. Thus, it can be used for relieving the symptoms of diabetes mellitus.

However, as medicinal herbs are usually mixed with other herbs and are seldom used alone in traditional Chinese medicine, it is hard to evaluate the effect of individual herbs on treating diabetes and its complications. Therefore, the aim of this review is to provide a comprehensive coverage of the individual herbs of Yuye Decoction regarding their active components and functional mechanisms for treating diabetes and its complications. It also provides an overview for researchers who intend to perform randomized control trials on YYD in the future.

Literature search

The search was done by using the specific search terms listed in Table 2 to gather information in PubMed regarding the use of YYD and its individual components in the treatment of diabetes respectively. After a preliminary search, articles related to YYD and its component herbs and published from 2009 to 2019 were screened. Articles whose topics matched diabetes and its complications were included. The basic information for each article such as country, experimental design (human, animal, cell based, chemical test) and results were extracted. Irrelevant or repeated articles were excluded.

After preliminary screening, clinical trials and mechanistic studies were analyzed respectively. For all human studies, the details of the study were extracted. Mechanistic studies were divided into animal studies, cell-based studies, animals & cell-based studies and chemical tests. These studies were then further grouped into different categories such as diabetes (not specific), insulin and metabolic syndrome; Type 1 diabetes; Type 2 diabetes; diabetic ophthalmopathy; diabetic nephropathy; diabetic retinopathy; diabetic cardiomyopathy; diabetic vascular complications; diabetic peripheral neuropathy; and diabetic cognitive impairment.

Table 1. Basic information of Yuye decoction

| Medicinal herbs | Medicinal part | Full scientific name | Weight of herbs in ancient medicina (qian/ equivalent g) | Ratio |
|-----------------|---------------|----------------------|---------------------------------------------------------|-------|
| Dioscorea opposite Thunb. | Rhizome | Dioscoreae Dioscoree Oppositae Rhizoma | 10/30 | 20 |
| Astragalus membranaceus (Fisch.) Bge. | Root | Astragali Membranacei Radix | 5/15 | 10 |
| Anemarrhena asphodeloides Bge. | Root | Anemarrhenae Rhizoma | 6/18 | 12 |
| Schisandra chinensis (Turcz.) Baill. | Fruit | Schisandraceae Chinese Fructus (SCF) | 3/9 | 6 |
| Trichosanthes kirilowii Maxim. | Root | Trichosanthis kirilowii Radix | 3/9 | 6 |
| Gallus gallus domesticus Brisson | Corneal endothelium | Galli Gigeri Endothelium Corneum | 2/6 | 4 |
| Pueraria lobata (Willd.) Ohwi | Root | Puerariae lobatae Radix | 1.5/4.5 | 3 |

J Transl Sci, 2020 doi: 10.15761/JTS.1000395 Volume 7: 2-16
Based on the key word search described in Table 2, 2978 articles were found in the PubMed database. Finally, 88 articles were included in our review after comprehensive screening. All 88 included studies came from Asia. Among them, most (73.8%) of the papers were from China (Tables 3 and 4).

**Results**

**Animal studies:** Forty-nine animal studies investigated the effects of YYD on diabetes and its complications (Tables 5-7).

**Diabetes (not specific), insulin and metabolic syndrome:** Fan et al. showed that a polysaccharide DOTP-80 from *Dioscorea opposita* Thunb roots had potent hypoglycemic activity [7]. Another study demonstrated that *Discorea batatas* extract could ameliorate insulin resistance in mice which were fed a high-fat diet [8]. In fructose-fed rats, a daily dose of 2 mg/kg astragaloside for 3 weeks improved metabolic syndrome and endothelial dysfunction [9]. In a cohort study, it was found that Huang-qi (*Astragalus membranaceus*) was one of the common Chinese medicines which could reduce the risk of diabetic ketoacidosis in diabetic patients [10].

**Type 1 diabetes (T1D):** Insulin is a hormone produced by the beta cells in the pancreas. It is important to transfer glucose into cells where glucose will be stored and further used for energy production. In type 1 diabetes, however, the pancreatic beta cells produce little or no insulin [11].

| Formula or medicinal herbs | Total | Not relevant | Animals studies | Cell-based studies | Chemical studies | Animals & cell-based studies | RCT | Cohort studies | Animals & cohort studies | Included |
|---------------------------|-------|-------------|----------------|-------------------|-----------------|-------------------------------|-----|----------------|--------------------------|---------|
| Yuye decoction            | 2     | 1           | -              | -                 | 1               | -                            | -   | -              | -                        | 1       |
| *Dioscorea opposita* Thunb.| 590   | 577         | 9              | 2                 | 1               | 1                            | -   | -              | -                        | 13      |
| *Astragalus membranaceus*  | 714   | 687         | 13             | 4                 | 2               | 6                            | 1   | 1              | -                        | 27      |
| *Anemarrhena asphodeloides*| 118   | 112         | 3              | 1                 | 1               | 1                            | -   | -              | -                        | 6       |
| *Schisandra chinensis* (Turcz.) Baill. | 767 | 756 | 6 | 1 | - | 4 | - | - | - | 11 |
| *Trichosanthes kirilowii* Maxim. | 171 | 167 | 1 | - | - | 1 | - | - | 1 | 3 |
| *Gallus gallus domesticus* Brisson | 12 | 12 | - | - | - | - | - | - | - | 0 |
| *Pueraria lobata* (Willd.) Ohwi | 604 | 577 | 17 | 4 | 1 | 5 | - | - | - | 27 |

| Total                     | 2978  | 88          |

| Table 2. Strings used in search |
|-----------------------------|

**Table 3. Results of literature search**

**Table 4. Number of papers by countries**

| Country  | Number of papers |
|----------|------------------|
| China    | 62               |
| South Korea | 7             |
| Taiwan   | 9                |
| Japan    | 3                |
| India    | 5                |
| Hong Kong| 2                |

| Table 5. Number of papers related to diabetic or its complications (DM: Diabetes (not specific); T1DM: Type 1 diabetes; T2DM: Type 2 diabetes; DO: Diabetic ophthalmopathy; DN: diabetic nephropathy; DR: diabetic retinopathy; DCM: diabetic cardiomyopathy; DVC: diabetic vascular complications; IR: insulin resistance; DPN: diabetic peripheral neuropathy; MetS: prediabetes & metabolic syndrome; DCI: diabetic cognitive impairment) |
|-----------------------------|
| **Formula or medicinal herbs** | **DM** | **T1DM** | **T2DM** | **DR** | **DN** | **DO** | **DCM** | **DVC** | **IR** | **DPN** | **MetS** | **DCI** | **Total** |
| Yuye decoction              | 1     | -       | -       | -      | -      | -      | -      | -      | -      | -      | -       | -       | 1        |
| *Dioscorea opposita* Thunb. | 2     | 3       | 6       | -      | -      | -      | -      | -      | 1      | 1      | -       | -       | 13       |
| *Astragalus membranaceus* (Fisch.) Bge. | 2     | -       | 8       | 2      | 6      | -      | -      | -      | 4      | -      | -       | -       | 3        |
| *Anemarrhena asphodeloides* Bge. | -     | -       | 2       | -      | 1      | 1      | -      | -      | -      | -      | -       | -       | 2        |
| *Schisandra chinensis* (Turcz.) Baill. | -     | -       | 8       | -      | 2      | -      | 1      | -      | -      | -      | -       | -       | 11       |
| *Trichosanthes kirilowii* Maxim. | -     | -       | -       | 2      | -      | -      | -      | -      | -      | -      | -       | -       | 3        |
| *Gallus gallus domesticus* Brisson | -     | -       | -       | -      | -      | -      | -      | -      | -      | -      | -       | -       | 0        |
| *Pueraria lobata* (Willd.) Ohwi | 1     | 2       | 9       | -      | 6      | 1      | 4      | 1      | 2      | 1      | -       | -       | 27       |
| Total                        | 7     | 5       | 33      | 2      | 17     | 2      | 9      | 2      | 3      | 1      | 3       | 4       | 88       |
Table 6. Different studies related to diabetic or its complications

| Studies Type         | DM   | T1DM | T2DM | DR  | DN  | DO  | DCM | DVC | IR  | DPN | MetS | DCI |
|----------------------|------|------|------|-----|-----|-----|-----|-----|-----|-----|------|-----|
| Animal studies       | 1    | 5    | 16   | 1   | 14  | 2   | 4   | -   | 1   | -   | 2    | 3   |
| Cell-based studies.  | 1    | -    | 3    | 1   | 1   | -   | -   | 3   | 1   | 1   | 12   |
| Animals & cell-based studies | 1    | -    | 11   | -   | 1   | -   | 2   | 2   | 1   | -   | -    | 18  |
| Animals & cohort studies | 1    | -    | -    | -   | -   | -   | -   | -   | -   | -   | -    | 1   |
| Chemical studies     | 3    | -    | 2    | -   | 1   | -   | -   | -   | -   | -   | -    | 6   |
| RCT                  | -    | -    | 1    | -   | -   | -   | -   | -   | -   | -   | -    | 1   |
| Case-control studies | 1    | -    | -    | -   | -   | -   | -   | -   | -   | -   | -    | 1   |
| Total                | 8    | 5    | 33   | 2   | 17  | 2   | 9   | 2   | 3   | 1   | 2    | 48  |

Table 7. Applications of herbal TCM and/or monomers in diabetes and its complications

| Animal studies | Extract | Topic                  | Duration | Model           | Pathways                                                                 | Results                                                                 |
|----------------|---------|------------------------|----------|-----------------|--------------------------------------------------------------------------|------------------------------------------------------------------------|
| Astragalus membranaceus (Fisch.) Bunge | NIL (Jian, W, et al. 2016) | Diabetic Retinopathy | 24 weeks | STZ rats | Through regulating multiple factors involved in the DR pathological pathway. | attenuating the increase in erythrocyte aggregation, plasma viscosity, and acellular vessel and pericyte loss; reversing the hyper-activation of JAK, the hyper-expression of VEGF, ICAM-1, and ET-1; normalizing the hypo-expression of PEDF and secludin in the retina of STZ-treated rats. |
| Polysaccharide AERP (Liu, Y, et al. 2019) | Polymeric AERP (JQ-JQ) (Li-hui Gao, et al. 2014) | Cognitive Dysfunction | 10 weeks | db/db mice | Through altering the gut microbiota | Alleviating the hyperglycemia, tissue impairment; inhibiting cognitive impairment; Modulating the composition of metabolites like SCFAs |
| Polysaccharide AERP | Refined-JQ (JQ-JQ) (Li-hui Gao, et al. 2014) | Prediabetes | 4 months | HFD-C57 mice | Through activating the AMPK signaling pathway | Reducing BW, TC, HOMA-IR; Enhancing the glucose tolerance; Improving insulin response; Activating liver glycogen synthesis; Improving GFR; Increasing the levels of phosphorylated AMPK and phosphorylated ACC. |
| Astragaloside IV (Wang, Y, et al. 2015) | Astragaloside IV (Wang, Y, et al. 2015) | Diabetic Nephropathy | 10 weeks | KKAY mice | Through inhibiting TGF-β/SMAD signaling pathway. | Down-regulating TGF-β1, SMAD2/3, α-SMA expression; alleviating renal interstitial fibrosis. |
| Astragaloside IV (Wang, Z, S, et al. 2015) | Astragaloside IV (Wang, Z, S, et al. 2015) | Diabetic Nephropathy | 8 weeks | STZ rats | Through decreasing ER stress | Reducing blood pressure and TG levels; Improving glucose tolerance and endothelium-dependent vasorelaxation. |
| Astragaloside IV (Zhang, N, et al. 2011) | Astragaloside IV (Zhang, N, et al. 2011) | Metabolic Syndrome | 3 weeks | fructose-fed rats | Through regulating NO/cGMP pathway | Reducing blood pressure and TG levels; Improving glucose tolerance and endothelium-dependent vasorelaxation. |
| NIL (Ruxuan Zhai, et al. 2019) | Astragalus polysaccharide (Liu, M, et al. 2010) | Diabetic Nephropathy | 12 weeks | STZ rats | Through inhibiting oxidative stress | Up-regulating nephrin, α-dystroglycan, Bcl-x; Down-regulating Hax and Nox; Ameliorating diabetic podocyte injury. |
| Astragalus polysaccharide (Chen, W, et al. 2009) | Astragalus polysaccharide (Chen, W, et al. 2009) | Diabetic Cardiomyopathy | 10 weeks | STZ hamsters | Through suppressing the local cardiac chymase–Ang II system | Ameliorating myocardial collagen deposition via suppression of chymase–MMP activation; Lowering levels of myocardial collagen type I and ratio of collagen type I/III; Suppressing cardiac MMP-2 and ProMMP-2 activities; Inhibiting heart chymase activation. |
| Astragalus polysaccharide (Gu et al. 2016) | Astragalus polysaccharide (Gu et al. 2016) | Diabetic Memory Impairment | 8 weeks | STZ rats | Through glucose and lipid metabolism. | Decreasing FPG, HbA1c, and insulin levels; Reversing memory impairment in the diabetic model; Lowering hippocampal MDA concentration. |
| NIL (Chen et al. 2017) | Astragalus polysaccharides (Chen et al. 2018) | Diabetic Cardiomyopathy | 15 weeks | db/db diabetic mice | Through the cardiac PPARα-mediated regulatory pathways. | Improving the myocyte TG accumulation & cardiac dysfunction; Normalizing energy metabolic derangements in diabetic hearts; Repressing the activation of PPARα target genes involved in myocardial fatty acid uptake and oxidation in diabetic hearts; Reversing PPARα-mediated suppression of genes involved in glucose utilization of diabetic hearts. |

Wan JH (2020) Review of the therapeutic effects of the traditional Chinese medicine yuye decoction on diabetes mellitus and its complications

J Transl Sci, 2020 doi: 10.15761/JTS.1000395 Volume 7: 4-16
| **Trichosanthes kirilowii** lectin (Zhang et al. 2019) | Diabetic Nephropathy | 8 weeks | STZ rat | Through inhibiting Notch signaling. | Attenuating STZ induced damages in renal function and structure; Increasing TNF-α & NO production; Suppressing IL-10 & Arg-1 production; Inhibiting induced inflammation by STZ; Blocking the polarization of macrophage into M1 type; Suppressing expression of Notch1, NIKD1, Hes1. |
| **Schisandra chinensis** (Turcz.) Baill. | | | | | |
| NIL (Hong et al. 2018) | T2DM | 10 weeks | db/db mice | Through suppressing lipid synthesis, oxidative stress, inflammation. | Decreasing plasma and hepatic TG & TC concentrations; Downregulating Hepatic expressions for fatty acid & TC synthesis; Upregulating beta-oxidation & TC export. Improving glucose tolerance; Increasing expression levels of antioxidative enzymes; Decreasing inflammatory cytokines, oxidative stress, leptin, insulin levels. |
| Acidic polysaccharide (Du et al., 2019) | T2DM | 8 weeks | STZ rats | Through protecting against β-cells apoptosis. | Decreasing FBG, TG, TC, LDL-C, MDA levels; Increasing insulin, HDL-C levels and SOD activity; Improving the pathological changes in pancreatic islet; Inhibiting the up-regulation of phosphorylated JNK, BAX and Cleaved Caspase-3 proteins; Increasing Bel-2 protein expression. |
| Ethanol extracts (Zhang et al. 2012) | Diabetic Nephropathy | 9 weeks | STZ rats | Through inhibiting the epithelial to mesenchymal transdifferentiation. | Lessening degree of fibrosis; Lowering the expressions of FN, α-SMA and PAI-1; Inhibiting the endothelial-myofibroblast transition |
| Schisandrae chinensis oil (An et al. 2015) | T2DM | 8 weeks | STZ rats | Through improving pancreatic β-cell function | Decreasing FBG, TC, TG levels, pancreatic MDA; Increasing SOD & CAT activities; Enhancing protein expression of Bel-2, PDX-1, GLUT2, GCK; Upregulating expression of anti-apoptotic genes; Increasing expression of glucose metabolism; Delaying islet cell apoptosis. |
| Schisandrae chinensis fruit extract (Zhang et al. 2012) | diabetic nephropathy | 7 weeks | STZ rats | Through preserving podocyte integrity by suppressing EMT. | Decreasing UAE & ACR; Attenuating glomerulosclerosis and protected against podocyte loss and integrity of the slit diaphragm; Preventing the EMT of podocytes. |
| A water-soluble polysaccharide (Niu et al. 2017) | T2DM | 28 days | STZ rats | Through antioxidant effect | Scavenging effect on superoxide anion free radical, hydroxyl radical, DPPH free radical; Increasing body weight; Improving the glucose tolerance; Reducing FBG; Elevating levels of FINS and value of ISI; Reducing the MDA content; Increasing GSHPX, CAT, SOD activities. |
| **Dioscorea opposita** Thunb. | | | | | |
| Yam dionisoorin, dipeptide NW (Wu et al. 2018) | T2DM | 135-day | C57BL/6J mice | Through impaired glucose tolerance controls | Lowering TC & low-density lipoprotein; Lowering TG contents; Reducing total visceral lipid contents; Lowering blood glucose levels. |
| Diosgenin (Sato et al., 2014) | T1DM | 2 days | STZ rats | Through activating the muscular GLUT4 signaling pathway | Increasing Serum DHEA level; Decreasing blood glucose level; Increasing GLUT4 translocation and Akt & PKC phosphorylation; Correlations were observed between blood glucose level, GLUT4 translocation level and muscular sex steroid hormone level 150 min after the administrations. |
| NIL (Zhi-Hong et al. 2014) | T2DM | 8 weeks | STZ rats | Through inhibiting polyol pathway | Decreasing blood glucose, insulin levels, adipose tissue weight; Improving glucose tolerance; Lowering plasma TG, TC, liver TG levels; Inhibiting the activity of AR; Restoring adiponectin expression in serum. |
| Allantoin (Go, H. K. et al. 2015) | T1DM | 31 days | STZ rats | Through modulating oxidative stress, | Decreasing blood glucose; Decreasing HbA1c, TC, low-density lipoprotein; Increasing insulin, GLP-1, C-peptide; Ameliorating antioxidative stress; Decreasing MDA; Increasing SOD; Reducing GSH |
| DOTP-80 (Fan, Y., et al. 2015) | Diabetes | 18 days | alloxan-induced mice | Through preventing oxidative damage of pancreatic β-cell. | Stimulating an increase in glucose disposal; Had strong hypoglycemic activity; Increasing the levels of antioxidative enzymes (SOD) activity |
| Ethanol extract (Cheng, Q., et al. 2015) | T2DM | 10 weeks | CD-1 (ICR) mice | Through improving glucose and lipid metabolism. | Improving glucose intolerance & normalize lipid profile; Increasing peripheral and hepatic insulin sensitivity; Decreasing serum free fatty acid level; Enhancing hepatic glucosekinase activity & glycogen content; Improving serum antioxidative activity; Decreasing fatty deposits in the liver of mice. |
| Allantoin (Niu, C. S. et al. 2010) | T1DM | 3 days | STZ rats | Through increasing β-endorphin secretion from the adrenal gland. | Decreasing plasma glucose levels in a dose related manner; Enhancing β-endorphin release from the isolated adrenal medulla of STZ diabetic rat in a dose-related manner; Increasing radioactive glucose uptake in isolated skeletal muscle; Increasing GLUT4 mRNA & protein levels in muscle, |
| DB extract (Kim, S. et al. 2012) | Early-stage obesity-induced insulin resistance | 7 weeks | HFD mice | Through activating the insulin signaling cascade leading to GLUT4 translocation | Reversing HFD-induced elevations in plasma glucose & insulin levels, HOMA-IR and oral glucose tolerance test values, Up-regulating the level of p-akt protein; Down-regulating the levels of p-ERK and p-S6K1 proteins in the adipose tissues; Reversing the HFD-induced decrease in the plasma membrane GLUT4 level; Improving glucose metabolism. |
| Plant/Extract                        | Disease Model | Duration | Treatment | Result/Effect                                                                 |
|-------------------------------------|---------------|----------|-----------|------------------------------------------------------------------------------|
| **Dioscorea opposita**              | T2DM          | 42 days  | STZ rats  | Through ameliorating lipid levels and oxidative stress.                      |
| Thunb polysaccharide-zinc (Zhang, Y. et al. 2018) |               |          |           | Decreasing the glucose and insulin levels; Reducing MDA contents; increasing SOD and T-AOC activities significantly in liver; Decreasing the levels of TCH3, TG, and LDL-C in serum; Increasing HDL-C level. |
| **Rhizoma Anemarrhenae**            |               |          |           |                                                                              |
| Sarsasapogenin (Yao-Wu Liu, et al. 2018) | Diabetic nephropathy | 9 weeks | STZ rats  | Through inhibiting NLRP3 inflammasome activation and AGEs-RAGE interaction |
| (Rashmi, S, et al.)                 |               |          |           | Ameliorating renal dysfunction; Decreasing UA1b, kidney weight index, SUA, FN, Col IV levels. Decreasing IL-18, NLRP3, activated caspase 1 levels, AGEs, RAGE levels in the renal cortex of diabetic rats. |
| Ethanol extract (Xuan Li, et al. 2013)) | Diabetic retinopathy | 12 weeks | STZ rats  | Through inhibiting AGE accumulation, polyol pathway activation and ROS overproduction. |
| (Liu, Y. W, et al.)                 |               |          |           | Increasing activities of SOD and GSH-Px in serum; Decreasing MDA, AGE levels in serum and sorbitol concentration in the lens in ERA-treated DO rats; Decreasing E/P ratio; Alleviating pathological changes of lens & retina; Ameliorating subnormal growth of pericytes induced by high glucose. |
| Total saponins from Rhizoma Anemarrhenae (Liu, Y. W, et al. 2012) | Diabetes-associated cognitive decline | 7 weeks | STZ rats  | Through a sum of reduction of Aβ accumulation and inflammation in brain |
| (Tripathi, Y. B, et al. 2017)       |               |          |           | Increasing A1–40, A1–42, TFN- levels in temporal cortex and hippocampus of diabetic rats with cognition impairment; Improving the learning ability of diabetic rats; Reducing A1–40, A1–42 and TFN- levels in cortex as well as A1–40 level in hippocampus; Inhibiting the elevation of TFN- level in serum; Decreasing FBG; increasing the body weight. |
| **Pueraria lobata** (Willd.)        |               |          |           |                                                                              |
| PTV-2 extract (Tripathi, Y. B, et al. 2017) | Diabetic Nephropathy | 20 days | STZ rats  | Through degrading the ECM accumulated in kidney tissues.                     |
| (Wu, K, et al. 2013)               | T1DM          | 14 days  | STZ rats  | Through elevating insulin expression and maintaining metabolic homeostasis. |
| Puerarin (Wu, K, et al. 2013)       |               |          |           | Reducing glycemia; Increasing serum insulin concentration; Improving dyslipidemia; Alleviating the STZ-lesioned pancreas tissue; Up-regulating intrapancreatic protein levels of IRS-1 & IGF-1; Increasing endogenous mRNA levels of skeletal muscle insulin receptor (InsR) and PPARa. |
| PTV-2r (Shukla, R, et al. 2017)     | Diabetic Nephropathy | 20 days | STZ rats  | Through suppressing oxidative stress and apoptosis.                          |
| (Chen, X. F, et al. 2018)           | T2DM          | 4 weeks  | STZ rats  | Through preventing the accumulation of intramyocellular lipids.              |
| Puerarin (Chen, X. F, et al. 2018)  |               |          |           | Alleviated dyslipidemia; Decreased the accumulation of intramyocellular lipids by upregulating the expression of a range of genes involved in mitochondrial biogenesis, oxidative phosphorylation, detoxification of ROS, oxidation of fatty acids in the muscle of diabetic rats; Decreasing the trafficking of fatty acid translocase/CD36 to the plasma membrane to reduce the uptake of fatty acids by myocytes. |
| NIL (Gao, K, et al. 2018)           | T2DM          | 8 weeks  | STZ rats  | Through altering features of the metabolic profiles and the gut microbiota.   |
| Flos Puerariae Extract (Yu, W, et al. 2014) | Diabetic Cardiomyopathy | 10 weeks | STZ rats  | Through inhibiting JNK and P38 MAPK signaling pathway.                       |
| NIL (Wang, W, et al. 2018)          | T2DM          | 8 weeks  | STZ rats  | Through the tight correlation between BAs and glucose-lipid metabolism status. |
| NIL (Wang, W, et al. 2018)          | T2DM          | 8 weeks  | STZ rats  | Through downregulating β cells apoptosis.                                    |
| PTV-2r (Shukla, R, et al. 2018)     | Diabetic Nephropathy | 20 days | STZ rats  | Through downregulating PKC-α & NF-κB pathway.                                |
| NIL (Wang, W, et al. 2018)          | T2DM          | 8 weeks  | STZ rats  | Decreasing the expression of INOS and inflammatory cytokines (IL-6 and TNF-α); Lowering the expression of PKC-α; Decreasing the expression of variation in NF-κB expression and pNF-κB. |
| Puerariae flos extract (Kubo, Koshi, et al. 2012) |               |          |           | Suppressing body weight gain & visceral fat accumulation; Alleviating the abnormal glucose tolerance & hyperinsulinemia; Increasing Acrp30; Suppressing liver enlargement, fatty degeneration, anti-inflammatory activity; Increasing gene expression for cholesterol synthesis rate-limiting enzyme HMG-CoA reductase, cholesterol catabolization enzyme Cyp7a1, bile salt export pump ABCB11, low-density lipoprotein receptor. |

J Transl Sci, 2020 doi: 10.15761/JTS.1000395
Volume 7: 6–16
Wan JH (2020) Review of the therapeutic effects of the traditional Chinese medicine yuye decoction on diabetes mellitus and its complications

| Extract | Topic | Model | Pathways | Results |
|---------|-------|-------|----------|---------|
| Astragaloside IV (Chen, X, et al. 2019) | Diabetic Nephropathy | Renal tubular epithelial cells (HK-2) | Through blocking the mTORC1/p70S6K signaling pathway. | Reducing EMT features in HK-2 cells; Inhibiting mTORC1/p70S6K pathway activation; Downregulating expression of snail & twist; Reducing secretion of FN and Col IV. |
| Astragalus polysaccharide (Ruixin Zhang, et al. 2018) | T2DM | 3T3-L1 preadipocytes | Through activating AMPK. | Increasing preadipocytes proliferation in a dose dependent manner; Increasing PCNA content; Enhancing intracellular lipid accumulation and mRNA expression of PPAR γ, C/CAAT/EBPα, FABP; Increasing 2-NBDG uptake; Elevating both mRNA and protein content of Glut4; Enhancing tyrosine phosphorylation of IRS 1 and phosphor-Akt content; Increasing phosphorylated AMPK content in the APS treated cells. |
| Astragalin (Ke, M, et al. 2012) | Diabetic Retinopathy | Müller cells | Through antioxidant activity | Decreasing the overexpression of VEGF in Müller cells; Altering the effects caused by high glucose; Alleviating endoplasmic reticulum stress. |
| Astragalus polysaccharide (Sun, S, et al. 2017) | H9C2 cell | Through inhibiting expression of proapoptotic proteins of extrinsic and intrinsic pathways. | Inhibiting high glucose-induced H9C2 cell apoptosis; Decreasing the expressions of caspases and the release of cytochrome C from mitochondria to cytoplasm; Modulating the ratio of Bcl-2 to Bax in mitochondria. |
| SCPP11 (Jin, D, et al. 2016) | T2DM | buffalo rat liver cells (BRL cells) | Through up-regulating the expression of GLUT-4 | Improving the glucose consumption in BRL cells; Increasing the protein expression of Akt, p-AMPK, GLUT-4 in BRL cells; Enhancing the mRNA expression levels of IRS-1, PI3K, Akt, GLUT-4, AMPK, PPARα in BRL cells. |
| Allantoin (Jörg Schweizer, et al. 2012) | Diabetes | C2C12 cell line | Through activating I2BR to increase glucose uptake into cells. | Increasing AMPK phosphorylation dose-dependently in C2C12 cells; Increasing glucose uptake in C2C12 cells. |
| Dioscorea opposita Thumb | T2DM | FL83B cells | Through inhibiting insulin resistance via the activation of INK. | Increasing glucose uptake & GLUT2 expression of insulin-resistant cells; Stimulating IRS tyrosol phosphorylation; Increasing p-Akt level to alleviate insulin resistance; Attenuating JNK and IR caused by TNF-α induction; Elevating the levels of p-IRSTyr and p-Akt expression to improve insulin sensitivity in the TNF-R-induced FL83B cells. |
| Anemarrhena asphodegioides Bge. | HT-22 cells | Through activating PPARα and subsequent down-regulating BACE1. | Elevating Aβ expression and Aβ42 level in HG-treated HT-22 cells; Increasing BACE1 protein, mRNA levels, enzymatic activity; Reversing reduced nuclear PPARα levels; Suppressing HG-induced decreases in cell viability of HT-22 cells. |
| NIR (FONG, Chi Chun, et al. 2011) | Diabetic Cardiomyopathy | H9c2 cells | Through up-regulating IRS/ AKT and INK pathways as well as inhibiting TNF and p38 pathways. | Promoting H9c2 cell viability & cell proliferation; Stimulating GM-CSF, CNF, IL-1β, IL-6, TNF-α, IL-1β, IL-6; Down-regulating expression of pro-inflammatory factors TNF-α and IFN-γ; Up-regulating anti-apoptosis related genes Caspase2c and Ppp3ca, several cardiovascular disease suppressors, anti-inflammatory mediators; Down-regulating pro-apoptotic related genes Caspase and Trnf-α. |

**Cell-based studies**

**Astragalus membranaceus (Finch.) Bunge**

**Extract** | **Topic** | **Model** | **Pathways** | **Results** |
|----------|----------|----------|--------------|-------------|
| Astragaloside IV | Diabetic Nephropathy | Renal tubular epithelial cells (HK-2) | Through blocking the mTORC1/p70S6K signaling pathway. | Reducing EMT features in HK-2 cells; Inhibiting mTORC1/p70S6K pathway activation; Downregulating expression of snail & twist; Reducing secretion of FN and Col IV. |
| Astragalus polysaccharide | T2DM | 3T3-L1 preadipocytes | Through activating AMPK. | Increasing preadipocytes proliferation in a dose dependent manner; Increasing PCNA content; Enhancing intracellular lipid accumulation and mRNA expression of PPAR γ, C/CAAT/EBPα, FABP; Increasing 2-NBDG uptake; Elevating both mRNA and protein content of Glut4; Enhancing tyrosine phosphorylation of IRS 1 and phosphor-Akt content; Increasing phosphorylated AMPK content in the APS treated cells. |
| Astragalin | Diabetic Retinopathy | Müller cells | Through antioxidant activity | Decreasing the overexpression of VEGF in Müller cells; Altering the effects caused by high glucose; Alleviating endoplasmic reticulum stress. |
| Astragalus polysaccharide | Diabetic Cardiomyopathy | H9C2 cell | Through inhibiting expression of proapoptotic proteins of extrinsic and intrinsic pathways. | Inhibiting high glucose-induced H9C2 cell apoptosis; Decreasing the expressions of caspases and the release of cytochrome C from mitochondria to cytoplasm; Modulating the ratio of Bcl-2 to Bax in mitochondria. |
| SCPP11 | T2DM | buffalo rat liver cells (BRL cells) | Through up-regulating the expression of GLUT-4 | Improving the glucose consumption in BRL cells; Increasing the protein expression of Akt, p-AMPK, GLUT-4 in BRL cells; Enhancing the mRNA expression levels of IRS-1, PI3K, Akt, GLUT-4, AMPK, PPARα in BRL cells. |
| Allantoin | Diabetes | C2C12 cell line | Through activating I2BR to increase glucose uptake into cells. | Increasing AMPK phosphorylation dose-dependently in C2C12 cells; Increasing glucose uptake in C2C12 cells. |
| Dioscorea opposita Thumb | T2DM | FL83B cells | Through inhibiting insulin resistance via the activation of INK. | Increasing glucose uptake & GLUT2 expression of insulin-resistant cells; Stimulating IRS tyrosol phosphorylation; Increasing p-Akt level to alleviate insulin resistance; Attenuating JNK and IR caused by TNF-α induction; Elevating the levels of p-IRSTyr and p-Akt expression to improve insulin sensitivity in the TNF-R-induced FL83B cells. |
| Anemarrhena asphodegioides Bge. | HT-22 cells | Through activating PPARα and subsequent down-regulating BACE1. | Elevating Aβ expression and Aβ42 level in HG-treated HT-22 cells; Increasing BACE1 protein, mRNA levels, enzymatic activity; Reversing reduced nuclear PPARα levels; Suppressing HG-induced decreases in cell viability of HT-22 cells. |
| NIR | Diabetic Cardiomyopathy | H9c2 cells | Through up-regulating IRS/ AKT and INK pathways as well as inhibiting TNF and p38 pathways. | Promoting H9c2 cell viability & cell proliferation; Stimulating GM-CSF, CNF, IL-1β, IL-6, TNF-α, IL-1β, IL-6; Down-regulating expression of pro-inflammatory factors TNF-α and IFN-γ; Up-regulating anti-apoptosis related genes Caspase2c and Ppp3ca, several cardiovascular disease suppressors, anti-inflammatory mediators; Down-regulating pro-apoptotic related genes Caspase and Trnf-α. |
**Table of Animal studies and Cell-based studies**

| Extract | Topic | Duration | Model | Pathways | Results |
|---------|-------|----------|-------|----------|---------|
| The saponins of *A. membranaceus* (Quan Liu, et al. 2017) | T2DM | 10 weeks | KK/AY mice/L6 myotubes | Through the insulin-dependent PI3K-AKT signaling pathway. | Decreasing fasting insulin levels; Improving the plasma lipid profiles; Increasing activity of SOD; Decreasing MDA & INOS levels; Elevating the insulin-stimulated glucose uptake with upregulated phosphorylation of AKT; Improving the phosphorylation levels of NF-κB p65, inhibitor of NF-κB (IκB α), c-Jun N-terminal kinase (JNK1/2) and extracellular-signal-regulated kinases (ERK1/2). |
| *Astragalus polysaccharides* (Jie Sun, et al. 2019) | T2DM | 12 weeks | C57BL/6 mice | Through activating hepatic insulin signaling. | Improving body weight & blood glucose/lipid levels; Recovering liver functions; Regaining insulin sensitivity; Improving the excessive and proapoptotic ER stress response; Inhibiting autophagy; Modulating the insulin-initiated phosphorylation cascades. |
| *Astragaloside IV* (Bin Leng, et al. 2018) | Diabetes | 8 weeks | STZ rats/HUVECs | Through inhibiting the TLR4/NF-κB signaling pathway. | Improving aortic endothelial function; Increasing eNOS expression & NO production; Decreasing the content of IL-6 and TNF-α and the expressions of VCAM-1, ICAM-1, TLR4, nuclear NF-κB p65. |
| *Astragalus polysaccharide* (Zou, F, et al. 2009) | T2DM | 8 weeks | STZ rats/C2C12 cells | Through an AMP activated protein kinase (AMPK)-dependent pathway | Improving the hyperglycemia status, insulin sensitivity, glucose uptake, activation level of AMPK; Alleviating glucose toxicity in cultured mouse cells by the activation of AMPK. |
| *Astragalus polysaccharide* (Chen, W, et al. 2015) | Diabetic Cardiomyopathy | 16 weeks | MHC-PPARα transgenic male mice/H9c2 cells | Through down-regulating the cardiac PPARα-mediated regulatory pathways. | Preventing myocardial triglyceride accumulation & cardiac dysfunction; Reducing free fatty acids utilization; Increasing glucose uptake; Downregulating the PPARα gene regulatory pathway involved in FFA-oxidation; Normalizing the suppression of PPARα target genes involved in glucose uptake and oxidation. |
| NIL (Hui, C, et al. 2017) | T2DM | 8 weeks | ob/ob mice/ T cells | Through improving abnormal immune and metabolic homeostasis. | Normalizing glucose and insulin level; Increasing the expression of Acrp30; Diminishing fat accumulation & lipogenesis; Promoting glucose uptake; Decreasing Ile, adenosine, TC; Increasing Gin levels in liver and VAT of ob/ob mice; Promoting the shift of pro-inflammatory to anti-inflammatory cytokines; Supressing T lymphocytes proliferation; Enhancing Tregs differentiation; Inhibiting DCs maturation; Attenuating DCs-stimulated T cells proliferation and secretion of IL-12p70 cytokine from DCs; Promoting the interaction of DCs with Tregs. |
| *Trichosanthes kirilowii* Maxim. | T2DM | 8 weeks | STZ rat/ HK-2 cells | Through inhibiting the LOX1/NFκB/caspase-9 signaling pathway. | Increasing the viability of HG-treated HK-2 cells; Inhibiting cell apoptosis; Attenuating STZ-induced histopathological damage & the inflammatory response in rat kidney tissues; Inhibiting the phosphorylation of IKKβ and NF-κB inhibitor protein (IκBα); Reducing the nuclear translocation of NF-κB (p65); Binding the binding of p65 to the CASP9 gene; Inhibiting luciferase activity in cells co-transfected with p65 and a wild-type caspase-9 construct instead of mutated caspase-9 constructs. |
| *Schisandra chinensis* (Trucz.) Baill. | T2DM | 6 weeks | HFD obese mice/C2C12 myotubes | Through activating AMPK. | Enhancing the phosphorylation of AMPK/ACC, Akt; Promoting glucose uptake in C2C12 myotubes; Increasing the expression of mitochondria biogenesis & fatty acid oxidation genes in C2C12 myotubes; Decreasing levels of fasting blood glucose & insulin; Improving glucose tolerance; Resucing decreased phosphorylation of AMPK and Akt; Stimulating expression of mitochondria biogenesis genes in skeletal muscle of HFD mice. |
| Water extracts of *schisandra chinensis* (Park, S, et al. 2009) | T2DM | 8 weeks | Px rats/ NCI-H716 cells | Through enhancing insulinotropic actions. | Improving glucose tolerance in an oral glucose tolerance test in Px rats; Increased cell mass by hyperplasia; Elevating IRS2 and PDX-1 expression in the islets. |

---

Wan JH (2020) Review of the therapeutic effects of the traditional Chinese medicine yuye decoction on diabetes mellitus and its complications.
Wan JH (2020) Review of the therapeutic effects of the traditional Chinese medicine yuye decoction on diabetes mellitus and its complications

| Study | Disease Area | Intervention | Effect | Additional Information |
|-------|--------------|--------------|--------|------------------------|
| Gomisin N (Arulkumar, N, et al. 2018) | T2DM | 6 weeks | HFD obese mice/ HepG2 | Through inhibiting CB1R-induced ER stress and improving insulin resistance & gluconeogenesis. Reversing 2-AG-mediated effects; Improved 2-AG-mediated impairment of insulin signaling; Inhibiting 2-AG-induced intracellular triglyceride accumulation & glucose production in HepG2 cells by downregulating lipogenesis & gluconeogenesis genes; Reducing HFD-induced increase in FBG & insulin levels; Downregulating HFD-induced expression of CB1R, ER stress markers, ceramide synthesis gene, gluconeogenesis genes in livers. |
| NIL (Jing Tian, et al. 2018) | Diabetic cardiomyopathy | 2 months | db/db mice/ H9C2 cardiomyocytes | Through improving mitochondrial lipid metabolism. Recovering diabetes-induced myocardial hypertrophy and diastolic dysfunction; Restoring mitochondrial structure & function; Enhancing SIRT1 & p-AMPKα protein levels; Decreasing expression of acetylated-PGC-1α & uncoupling protein 2 protein; Restoring depletion of NRF1 & TFAM levels in diabetic hearts and H9C2 cardiomyocytes. |
| Dispo85E (Peng, K. Y, et al. 2011) | Diabetic Vascular Complications | 8 weeks | AGEs-induced diabetic mice/ NPCs | Through enhancing the clearance of AGEs by HGF-induced autophagic-lysosomal pathway. Enhancing endocytosis & degradation activity of AGEs in hepatic NPCs; Positively correlating HGF expression level with clearance capacity of the AGEs in NPCs; Increasing hepatic HGF messenger RNA expression levels; Decreasing serum AGEs level in diabetic mice; Improving the function of retina and kidneys. |
| Rhiza Alom (Yeno, K, et al. 2015) | T2DM | 7 days | STZ rats/ Marine 3T3-L1 preadipocytes & LKB1-deficient Hela cells | Through mediating the activation of AMPK. Enhancing glucose-lowering effects of exogenous insulin administration i; Reducing FBG, serum insulin levels; Increasing the size and the number of insulin-producing beta cells in KK-Ay mice; Improving glucose infusion rate; Increasing phosphorylation of AMPK & its downstream target, ACC in 3T3-L1 cells; Activating AMPK in a LKB1-independent manner. |
| Pueraria lobata root extract | (SUN, Ran, et al. 2019) | T2DM | not mention | STZ rats/ HepG2 cells | Through inhibiting PTP1B. Exhibiting high PTP1B inhibitory activity with IC50, Increasing the glucose uptake by two times; Decreasing blood glucose (AUC). |
| NIL (ZHAI, Wenwen, et al. 2019) | Diabetic Vascular Injury | 7 weeks | STZ rats/ HUVECs | Through reducing oxidative stress. Decreasing serum levels of insulin, NO, H2O2, MDA, sICAM-1, s-VCAM-1; Increasing SOD & CAT levels; Improving pathological alterations of aorta; Inhibiting increased expression of ICAM-1, VCAM-1, NO2, and NOX4 in aorta; Suppressing HGF-induced endothelial ROS formation, ICAM-1, VCAM-1, NOX4 expression, monocyte-endothelial adhesion. |
| Nill (YEO, Jiyoung, et al. 2011) | T2DM | 3 weeks | db/db mice/ C2C12 cells | Through alleviating ER stress. Inhibiting TNF-α-stimulated IkBα/NF-kB signaling; Attenuating ER stress in HepG2 cells; Reducing FBG & HbA1c levels; Improving postprandial glucose levels; Enhancing insulin sensitivity; Decreasing plasma free fatty acid, TG, TC. |
| Puerarin (CHEN, Xinli, et al. 2018) | T2DM | 4 weeks | STZ rats/ L6 skeletal muscle cells | Through improving insulin sensitivity. Enhancing μ-opioid receptor expression & phosphorylation; Increasing insulin-stimulated glucose transporter 4 translocation to the plasma membrane in the skeletal muscle of diabetic rats. |
| Puerarin (HUANG, Fang, et al. 2012) | Endothelial Insulin Resistance | not mention | not mention/ HUVECs | Through inhibiting inflammation and attenuating endothelial insulin resistance. Inhibiting IkKβ-NF-κB activation; Decreasing TNF-α & IL-6 production; Downregulating relative gene overexpression; Attenuating PA-induced phosphorylation of IRS-1 at S307; Ameliorating insulin-mediated tyrosine phosphorylation of IRS-1; Increasing insulin-mediated NO production |

**Chemical studies**

| Astragalus membranaceus (Fisch.) Bunge | Extract | Topic | Pathways | Results |
|----------------------------------------|---------|-------|----------|--------|
| Astragalosides (Motomura, K, et al. 2009) | Diabetic Nephropathy | Through inhibiting AGEs | Inhibiting the formation of both CML and pentosidine; Astragaloside V had the strongest inhibitory effect among all if the isolated compounds. |
| Refined-IQ (IQ-R) (Chang, Y. X, et al. 2015) | Diabetes | Through a potent anti-diabetic activity. | Scavenging free radicals; inhibiting α-glucosidase, aldose reductase, α-amylase and lipase. |
| NILL (Liu, J, et al. 2014) | Diabetes | Through the temperature-correlated mobility scale | Achieving the optimization of the system conditions for the MEKC separations in the temperature-correlated mobility scale by correcting for viscosity changes; Monitoring the influence of the operating temperature in a more distinct way. |

| Anemarrhena asphodeloides Bge. | NIL (Yin-Shiou Lin, et al. 2016) | T2DM | Through DPP-IV inhibitions. | Lowering the area under the curve (AUC0–120) of blood glucose and DPP-IV activity; Elevating the AUC0–120 of blood insulin. |
|----------------------------------------|---------|-------|----------|--------|
| Mangiferin (Aihua Lin, et al. 2019) | T2DM | Through establishing a rapid, reliable, sensitive LC/MS-MS method | The tissue distribution study results showed that mangiferin displayed rapid and wide distribution in plasma and tissues and it could not cross the BBB. |
| Pueraria lobata (Willd.) Ohwi | Pueraria lobata extracts (DENG, Wenji, et al.2019) | Diabetes | Through alleviating the oxidative stress & improving the pancreatic function. | Producing significant hypoglycemic effects; Providing outstanding intestinal permeability and transepithelial transport aptness |
It was suggested that acute administration of diosgenin, a compound of Dioscorea, could reduce hyperglycemia with increased muscular steroidogenesis in type 1 diabetes rats [12]. Allantoin, another active constituent in Dioscorea batatas, could improve the function of β-cells to maintain normal plasma insulin and glucose levels in rats [13]. Another study also showed that allantoin could increase GLUT4 gene expression in muscle by increasing β-endorphin secretion from the adrenal glands in diabetic rats [14]. It was found that puerarin tubers could protect against STZ-induced diabetes by regulating apoptosis-related protein expression to alleviate the injury from oxidative stress [21].

Type 2 diabetes (T2D): Type 2 diabetes is the most common type of diabetes. It is characterized by insulin resistance in which the human body cannot fully respond to insulin. As insulin cannot exert its action properly, the blood glucose level keeps rising. Finally, the pancreas will be exhausted, and hyperglycemia will result [17].

Chen et al. showed that Jia-Wei-Jiao-Tai-Wan (JWJTW), which contains Astragalus membranaceus, could ameliorate T2D by improving β cell function and reducing insulin resistance in diabetic rats [18]. Astragalus polysaccharide (APS) is an important bioactive component of Astragalus membranaceus. It was reported that APS could regulate part of the insulin signaling in insulin-resistant skeletal muscle in KKAY mice [19].

Hong et al. stated that Schisandra chinensis fruit-supplemented Korean rice cookie called dasik (RCD) had lipid-lowering and anti-diabetic effects [20]. It was found that an acidic polysaccharide from Schisandra chinensis had a therapeutic effect on T2D rats by regulating apoptosis-related protein expression to alleviate the injury from oxidative stress [21]. A water-soluble polysaccharide (SSPW1) from Schisandra chinensis had antioxidant activities and anti-diabetic effect on T2D rats [22]. Another study disclosed that Schisandra chinensis oil could improve pancreatic β-cell function by enhancing the antioxidant potential of the pancreas [23].

Wu et al. demonstrated that, after treatment of C57BL/6 mice on a high-fat diet with yam dioscorin for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24]. A daily dose of 8.02 g/kg of a functional formula diet including Rhizoma dioscorea, for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24]. A daily dose of 8.02 g/kg of a functional formula diet including Rhizoma dioscorea, for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24]. A daily dose of 8.02 g/kg of a functional formula diet including Rhizoma dioscorin for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24]. A daily dose of 8.02 g/kg of a functional formula diet including Rhizoma dioscorin for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24]. A daily dose of 8.02 g/kg of a functional formula diet including Rhizoma dioscorin for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24]. A daily dose of 8.02 g/kg of a functional formula diet including Rhizoma dioscorin for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24]. A daily dose of 8.02 g/kg of a functional formula diet including Rhizoma dioscorin for 135 days, weight gain was reduced, and impaired glucose tolerance was improved [24].
Kubo et al. reported that *Puerariae flos* extract alleviated metabolic diseases in western diet-loaded and spontaneously obese mice representing an animal model of type 2 diabetes [28]. Puerarin (PUE) is a natural isoflavonoid isolated from the root of *Pueraria lobata*. Previous research had shown that PUE promoted fatty acid oxidation by increasing mitochondrial oxidative capacity and biogenesis in skeletal muscle of diabetic rats [29]. More recent studies confirmed that upregulation of UCP2-glucoronsyltransferases 1a1 and 1a7 are involved in altered PUE pharmacokinetcs in T2D rats [30]. Qijian mixture, a new traditional Chinese medicine (TCM) formula containing *Pueraria lobata* could ameliorate T2D by altering metabolite profiles and gut microbiota [31]. Ge-Gen-Jiao-Tai-Wan (GJJTW) formula, which is composed of *Puerariae montana* var. lobata (Willd.), showed a hypoglycemic effect via the tight correlation between BAs and glucose/lipid metabolism status [32]. It was suggested that another Chinese Herbal Formula called Shenzhu Tiaoi Granule elicited metabolic improvement in T2D rats by modulating the gut microbiota [33].

**Diabetic nephropathy:** Diabetic nephropathy (DN) is one of the major complications of diabetes and is the major leading cause of end stage renal disease (ESRD). It is a progressive disease characterized by rising urinary albumin excretion and declining renal functions [34].

Astragaloside IV (AS-IV) is derived from *Astragalus membranaceus*, a widely used herbal medicine in China. Wang et al. showed that AS-IV attenuated proteinuria in STZ rats by inhibiting endoplasmic reticulum stress [35]. Another study found that AS-IV ameliorated renal injury in STZ rats by inhibiting NF-kB-mediated inflammatory genes expression [36]. According to Wang et al., AS-IV administered to diabetic mice at a dose of 40 mg/kg daily for 10 weeks could delay the renal fibrosis process by influencing the TGF-β/SMADs signaling pathway and down-regulating TGF-β1, SMAD2/3 and α-SMA expression [37]. It was suggested that a novel renoprotective compound, which is composed of *Astragaloside membranaceus* and *Panax notoginseng*, could synergistically protect against podocyte injury in STZ-induced diabetic rats [38].

It was shown that *Trichosanthes kirilowii* lectin ameliorated STZ-induced kidney injury via modulating the balance between M1/M2 phenotype macrophage [39]. Zhang et al. observed that *Schisandra chinensis* fruit extract attenuated albuminuria and protected podocyte integrity in STZ-induced diabetic rats [40]. Another investigation revealed that an ethanol extract from *Fructus Schisandrae chinensis* prevented renal interstitial fibrosis [41].

Sarsasapogenin is a major sapogenin from rhizomes of *Anemarrhena asphodeloides* Bunge. It was shown that it could markedly ameliorate DN in rats via inhibiting NLRP3 inflammasome activation and AGEs-RAGE interaction [42].

PTY-2 is an active fraction of tubers from *Pueraria tuberosa*. According to Yamini et al., it could attenuate diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in the kidneys of diabetic rats [43]. In another study by Shukla et al., PTY-2 exerted antioxidant and antiapoptotic effects on DN. Later, the same group discovered that PTY-2 alleviated the kidney damage induced by chronic hyperglycemia and delayed the development of DN by suppressing the expression of HIF-1a and VEGF, thereby restoring the expression of nephrin [44]. It was also found that PTY-2 inhibited iNOS and IL-6 through suppressing the PKC-α and NF-κB pathway in treating DN [45]. Another study suggested that PUE protected against DN by attenuating oxidative stress [46]. A Radix Puerariae and Fructus Crafaegi mixture could inhibit DN via decreasing of AKT/Pi3K [47].

**Diabetic retinopathy:** Diabetic retinopathy induced by diabetes involves the retinal capillaries, arterioles and venules. It is accompanied by leakage or occlusion of the small vessels [48].

Jian et al. found that Fufang Xueshuantong capsules, which contain *Astragalus membranaceus*, could attenuate STZ-induced retinal lesions in rats [49].

**Diabetic opthalmopathy:** Diabetic ophthalmopathy is a disease induced by diabetes. It impairs patients’ eyesight and even causes blindness [50].

It was shown that *Anemarrhena asphodeloides* rhizomes could counteract diabetic ophthalmopathy progression in STZ-induced diabetic rats [51]. Zhang et al. showed that PUE could prevent cataract development and progression in diabetic rats through the Nrf2/HO-1 signaling pathway [52].

**Diabetic cardiomypathy:** Diabetic cardiomopathy (DCM) is a diabetes-related complication characterized by left ventricular (LV) hypertrophy, myocardial fibrosis, compromised myocardial function and is a leading cause of morbidity and mortality [53].

The study by Chen et al. revealed that *Astragalus* polysaccharides inhibited DCM in hamsters by suppressing heart chymase activation [54]. It was also demonstrated that *Astragalus* polysaccharides improved PPARα-mediated lipotoxicity in DCM [55]. Yu et al. showed that Flos Puerariae Extract could prevent myocardial apoptosis by attenuating oxidative stress in STZ-Induced diabetic mice [56]. Recently, Guo et al. suggested that PUE reduced ischemia/reperfusion-induced myocardial injury in diabetic rats through upregulating vascular endothelial growth factor A/angiotensin-1 and suppressing apoptosis [57].

**Diabetic cognitive impairment:** Diabetes and insulin resistance affect the central nervous system as well as the development of cognitive and memory impairments which diminish the quality of life of diabetic patients [58].

*Astragalus* polysaccharides (APS) are active constituents of *Astragalus membranaceus*. Research finding by Liu et al. demonstrated that APS could improve cognitive dysfunction by altering the gut microbiota in diabetic mice [59]. Dun et al. also found that APS could improve memory in rats with STZ-induced diabetes. This was associated with its effects on glucose and lipid metabolism, antioxidant activity and insulin resistance [60]. In addition, Liu et al. showed that total saponins from Rhizoma Anemarrheneae alleviated diabetes-associated cognitive decline in rats via reduction of amyloid-beta in the brain [61].

**Cell-based studies:** Twelve cell-based studies investigated the effects on diabetes and its complications (Table 7).

**Diabetes (not specific), insulin and metabolic syndrome:** Allantoin is an active principle of the yam. Allantoin could activate I_s,R to enhance glucose uptake into cells. Hence it may be a new target for antidiabetic therapy [62]. Kakkalide is the predominant isoflavone extracted from the flowers of *Pueraria lobata*. Zhang et al. demonstrated that Kakkalide inhibited reactive oxygen species (ROS)-associated inflammation and ameliorated insulin-resistant endothelial dysfunction due to effects on insulin receptor substrate 1(IRS-1) function [63].

Type 2 diabetes: It was shown that *Astragalus polysaccharide* improved insulin sensitivity via AMPK activation in ST3-L1 adipocytes [64]. The *Schisandra polysaccharide* also increased glucose consumption by up-regulating the expression of GLUT-4 in buffalo rat liver cells
the study of Jin et al. [65]. It was reported that Dioscorea polysaccharide manifested inhibitory effects on TNF-α-induced insulin resistance in mouse FL83B cells [66].

**Diabetic retinopathy:** Ke et al. showed that astragalin extracted from Astragalus membranaceus, attenuated the overexpression of VEGF in Müller cells and alleviated the effects caused by a high glucose level [67].

**Diabetic nephropathy:** Chen et al. suggested that Astragaloside IV ameliorated high glucose-induced renal tubular epithelial-mesenchymal transition by blocking mTORC1/p70S6K signaling in HK-2 cells [68].

**Diabetic cardiomyopathy:** Astragalus polysaccharides could attenuate DCM by inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose stimulated H9C2 cells [69]. Another study revealed that PUE inhibited high glucose-induced Nlrp3 inflammasome formation and activation by ROS-dependent oxidative pathway [70]. Besides, Danshen–Gegen decoction, which contains Pueraria lobata, had been proven to display a proliferative effect on rat cardiac myoblasts H9c2 via MAPK and insulin pathways [71].

**Diabetic peripheral neuropathy:** Diabetic peripheral neuropathy, which is one of the most debilitating complications of diabetes, is characterized by axonal degeneration, demyelination, and atrophy [72]. Xue et al. suggested that PUE may protect Schwann cells against glucose fluctuation-induced cell injury by inhibiting apoptosis and oxidative stress [73].

**Diabetic cognitive impairment:** It was showed that sarsasapogenin (Sar), an active component purified from Rhizoma Anemarrhenae, suppressed Aβ overproduction induced by a high glucose level in HT-22 cells [74].

**Animal studies & cell-based studies:**

- Diabetes (not specific), insulin and metabolic syndrome: Astragaloside IV improved vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway in vivo and in vitro [75].

- According to Huang et al., puerarin attenuated endothelial insulin resistance by inhibiting the inflammatory response in an IKKβ/IRS-1-dependent manner [76].

**T2DM:** It was reported that APS could potentially activate hepatic insulin signaling in vivo and in vitro [77]. Another study revealed that APS could alleviate glucose toxicity and restore glucose homeostasis in diabetic states by activating AMPK [78]. A Chinese herbal medicine preparation JQ-R, which contains Astragalus membranaceus, manifested anti-diabetic effects in vivo and in vitro [79]. Another decoction called Dangguiuliu (DGLHD) exerted anti-insulin resistance and antisteatotic effects by improving abnormal immune and metabolic homeostasis [80].

- Gomisin N (GN) is a lignan derived from Schisandra chinensis. Jung et al. showed that GN exerted anti-hyperglycemic effects by AMPK activation [81]. Another study suggested that GN protected against hepatic cannabinoid type 1 receptor-induced insulin resistance and gluconeogenesis [82]. In Huang-Lian-Jie-Du-Tang supplemented with Schisandra chinensis and Polygonatum odoratum Druce, glucose tolerance was improved by potentiating insulinotropic actions in islets [83].

- In the study of Han et al., Rhizoma Anemarrhenae extract ameliorated hyperglycemia and insulin resistance through activating AMP-activated protein kinase in vivo as well as in vitro [84]. The antidiabetic potential of Pueraria lobata root extract through promoting insulin signaling and inhibiting PTP1B was demonstrated by Sun et al. [85]. Besides, PUE acted on the skeletal muscle to improve insulin sensitivity in diabetic rats involving μ-opioid receptor [86]. In a multi-herbal extract including Pueraria lobata, Yeo et al. showed that PUE had therapeutic effects for treating type 2 diabetes in both cells and animal models [87].

**Diabetic nephropathy:** Trichosanthes kirilowii lectin alleviated DN by inhibiting the LOX1/NF-kB/caspase-9 signaling pathway both in vivo and in vitro [88].

**Diabetic cardiomyopathy**

A recent study by Chen et al. showed that APS repressed myocardial lipotoxicity in a PPARα-dependent manner in vitro and in vivo [89] Shengmian san, which includes Schisandra chinensis, was shown to alleviate diabetic cardiomyopathy by improving mitochondrial lipid metabolic disorder [90].

**Diabetic vascular complications:** The vascular complications of diabetes are the most serious manifestations of the disease. Dispo85E is the extract of rhizomes from Dioscorea alata L. It could enhance the clearance of advanced glycation end products (AGEs) through hepatocyte growth factor (HGF)-induced autophagic-lysosomal pathway for treating diabetic vascular complications [91]. Another study suggested that an aqueous extract of the pair of herbs Salvia miltiorrhiza Bunge-Radix Puerariae ameliorated diabetic vascular injury by inhibiting oxidative stress in STZ-induced diabetic rats [92].

**Chemical studies**

**Diabetes (not specific), insulin and metabolic syndrome:** A study by Liu et al. revealed a successful application of temperature-correlated mobility theory for separating the main lignans from Schisandra chinensis Fructus and its prescription Yuye Decoction in MEKC [93]. Jinqi Jiangtang Tablet, which is a traditional Chinese anti-diabetic formula containing Astragalus membranaceus, was demonstrated to scavenge free radicals and inhibit α-glucosidase, aldose reductase, α-amylase and lipase for treating diabetes [94]. Another study suggested that selenium-layered nanoparticles used for oral delivery of mulberry leaf and Pueraria lobata extracts expressed a better antihyperglycemic activity [95].

**T2DM:** Lin et al. conducted a tissue distribution study of mangiferin after intragastric administration of the mangiferin monomer, Rhizoma Anemarrhenae, and Rhizoma Anemarrhenae-Phellodendron decoctions in normal or type 2 diabetic rats by LC-MS/MS respectively. Results showed a lower mangiferin distribution in pancreas and intestine of diabetic rats administered with the same dose of the herb pair than that in normal rats [96]. Lin et al. reported that synthetic peptide derived from hydrolysis of yam dioscorin in silico exhibited dipeptidyl peptidase-IV inhibitory activity and improvements in oral glucose tolerance in normal mice [97].

**Diabetic nephropathy:** A study by Motomura et al. suggested that astragalosides isolated from Astragalus Radix inhibited the formation of advanced glycation end products and astragaloside V had the strongest inhibitory effect. Thus, it could be used to treat diabetic nephropathy [98].

**Human studies**

**Randomized clinical trials (RCT):** There was only one RCT in 88 included studies. This RCT study included 43 newly diagnosed type.
Wan JH (2020) Review of the therapeutic effects of the traditional Chinese medicine yuye decoction on diabetes mellitus and its complications

2 diabetic patients, who had not used any antidiabetic drugs prior to the study. Then, they were randomly assigned into TCM and placebo groups. TCM mixture contains Astragalus membranaceus. Results showed that TCM mixture could ameliorate insulin resistance in type 2 diabetes, so it is safe and effective for diabetic patients [99].

Case-control study design: A study by Lien et al. retrieved records of samples from the registry for catastrophic illness patients in the National Health Insurance Research Database (NHIRD). Patients with T1DM in 2000–2011 were designated as cases (TCM users) and controls (non-TCM users) based on a frequency (1:4) matched case-control design. TCM treatment for patients with T1DM were then analyzed. The incidence of diabetic ketoacidosis and the annual costs of emergency visits and hospitalizations were also evaluated for all causes. Results showed that TCM may have a substantial positive impact on the management of T1DM [100].

A retrospective cohort study and an animal study: Lo et al. conducted a retrospective cohort study to analyze the usage of Chinese herbs in patients with type 2 diabetes in Taiwan and showed that Trichosanthes kirilowii Maxim. (TK) was the most frequently used Chinese medicinal herb. An animal study showed that TK protein enhanced the clearance of glucose in a dose-dependent manner [101].

Discussion

Composition: According to the ancient medical literature “yixue zhongzhong canxi lu”, the composition of YYD is 30 g (Dioscorea opposite Thunb.); 15 g (Astragalus membranaceus (Fisch.) Bge.); 18 g (Anemarrhena asphodeloides Bge.); 9 g (Schisandra chinensis (Turcz.) Baill.); 9 g (Trichosanthes kirilowii Maxim.); 6 g (Gallus gallus domesticus Brisson); and 4.5 g (Pueraria lobata (Willd.) Ohwi). The weight ratio of the herbs is 20:10:12:6:6:4:3.

Dosage: In animals’ studies, the dose of herbs or formula administered ranged between 0.5 mg/kg and 12.15 g/kg per day. In RCT, the dose of formula administered was 9 mg/day. In all human, animal and cell studies, the dosage employed was not mentioned in only 4 out of 82 papers. The dose used was stated explicitly in 95.1% of the papers.

Duration: In all human and animal studies, 3 out of 70 papers did not mention the duration of the study. 95.7% of the papers stated the duration clearly. In animal studies, the duration of treatment ranged from 2 days to 100 days. In RCT, the duration of treatment 1 was 3 months.

Toxicity: No study indicated the toxicity of medicinal herbs or formulas. No toxicity in human trials has been reported.

The quality of studies: All human, animal and cell studies stated the ratio of the individual herbs if a formula was used. All studies stated the origin, the extraction method and the composition of each constituent herb. However, some studies did not provide the name of pharmaceutical companies and the batch number of the concentrated tablets used in the experiments. There was only one RCT among all the studies examined. The follow-up study details were not stated in this randomized clinical trial. The method of randomization and the placebo detail were not stated clearly. There should be more well-designed RCT in the future in order to provide more and stronger evidence.

The statistics of YYD: There are seven medicinal herbs in YYD. There were research papers on all the herbs except Gallus gallus domesticus Brisson. Among them, the largest number of research papers (30.7%) were about Astragalus membranaceus (Fisch.) Bge. and Pueraria lobata (Willd.) Ohwi. T2DM was studied most (37.5%) of the research papers while DN was the most (19.3%) studied diabetic complication (Table 5).

Most, 49 out of 88 (55.7%) of the papers, reported animal studies. About 20.5% papers were animal & cell-based papers (Table 6). It is encouraging to do so as in vivo and in vitro studies gave more comprehensive insight on the signaling pathways involved. The protective effects against several diabetic complications are more impressive in in vivo and in vitro models.

Conclusion and future perspectives

The various medicinal herbs in YYD exhibit their antidiabetic activities through different signaling pathways which are illustrated in Figure 1. In compound level all medicinal herbs in YYD, except
**Authors’ contributions**

Kalin YB ZHANG and Sydney CW TANG conceived and designed the study. Jack H W AN drafted manuscript. KH LAM, TH SONG, PS HO, Leanne L LEUNG, TL FONG, NC LAU, CH WONG and TL FONG, NC LAU, CH WONG and JF Wang reviewed and edited the manuscript. All authors read and approved the manuscript.

**References**

1. Bell GI, Polonsky KS (2001) Diabetes mellitus and genetically programmed defects in β-cell function. Nature 414: 788-791. [Crossref]
2. Wild S, Roglic G, Green A, Sicree R, King, et al. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 27: 1047-1053. [Crossref]
3. Stohsouwer CDA (2018) Microvascular dysfunction and hyperglycemia: A vicious cycle with widespread consequences. *Diabetes 67*: 1729-1741. [Crossref]
4. Wang SL, Liu DS, Liang ES, Gao YH, Cui Y, et al. (2015) Protective effect of allicin on high glucose/hypoxia-induced aortic endothelial cells via reduction of oxidative stress. *Experimental and Therapeutic Medicine* 10: 1340-1400.
5. Alwan AD, Galea G, Stuckler D (2011) Development at risk: addressing noncommunicable diseases at the United Nations high-level meeting. *Bull World Health Organ* 89: 546-546A.
6. Fan Y, He Q, Luo A, Wang M, Luo A, et al. (2015) Characterization and antihyperglycemic activity of a polysaccharide from Dioscorea opposita Thunb roots. *Journal of Medicinal Plants Research* 9: 3368-3379.
7. Fan Y, He Q, Luo A, Wang M, Luo A, et al. (2015) Characterization and antihyperglycemic activity of a polysaccharide from Dioscorea opposita Thunb roots. *Journal of Medicinal Plants Research* 9: 3368-3379.
8. Zhang N, Wang XV, Mao SL, ZhaoF (2011) Astragaloside IV improves metabolic syndrome and endothelium dysfunction in fructose-fed rats. *International Journal of Molecular Sciences* 12: 3896-3907.
9. Go HK, Rahman M (2015) Antidiabetic effects of yam (Dioscorea batatas) and its active constituent, allantoin, in a rat model of streptozotocin-induced diabetes. *Nutrients* 7: 8532-8544. [Crossref]
10. Niu, C. S, Chen, W, Wu, H. T, Cheng, K. C, Wen, Y. J, Lin, K. C, Cheng, J. T. (2010) Decrease of plasma glucose by allantoin, an active principle of yam (Dioscorea spp.), in streptozotocin-induced diabetic rats. *Journal of Agricultural and Food Chemistry* 58: 12031-12035. [Crossref]
11. Wu K (2013) Anti-diabetic effects of puerarin, isolated from Pueraria lobata (Willd.), on streptozotocin-diabeticogenic mice through promoting insulin expression and ameliorating metabolic function. *Food and Chemical Toxicology* 60: 341-347. [Crossref]
12. Srivastava S (2018) Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY2 against STZ-induced pancreatitis. *Biomedicine and Pharmacotherapy* 97: 330-338. [Crossref]
17. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813. [Crossref]

18. Chen G, Yang X, Yang X (2017) Jia-Wei-Jiao-Tai-Wan ameliorates type 2 diabetes by improving β cell function and reducing insulin resistance in diabetic rats. BMC Complementary and Alternative Medicine 17: 507. [Crossref]

19. Liu M (2010) Astragalus polysaccharide improves insulin sensitivity in KK/AY mice: regulation of PKB/GLUT4 signaling in skeletal muscle. Journal of Ethnopharmacology 127: 32-37. [Crossref]

20. Hong SH (2018) Hypolipidemic and anti-diabetic effects of functional rice cookies in high-fat diet-fed ICR mice and db/db mice. Journal of Medicinal Food 21: 535-543. [Crossref]

21. Du XX (2019) Hypoglycemic effect of acidic polysaccharide from Schisandra chinensis on T2D rats induced by high-fat diet combined with STZ. Biological and Pharmaceutical Bulletin 42: 1275-1281. [Crossref]

22. Niu J (2017) In vitro antioxidant activities and anti-diabetic effect of a polysaccharide from Schisandra sphenanthera in rats with type 2 diabetes. International Journal of Biological Macromolecules 94: 154-160. [Crossref]

23. An L (2015) Protective effect of Schisandrin chinensis oil on pancreatic β-cells in diabetic rats. Endocine 48: 818-825. [Crossref]

24. Wu G C (2018) 135 day-interventions of yam dioscorin and the dipeptide asn-trp (mw) to reduce weight gains and improve impaired glucose tolerances in high-fat diet-induced e57b6/b mice. Journal of Agricultural and Food Chemistry 66: 645-652.

25. Cheng Q (2015) Anti-diabetic effects of the ethanol extract of a functional formula diet in mice fed with a fructose-fat-rich combination diet. Journal of the Science of Food and Agriculture 95: 401-408.

26. Wang ZH (2014) Antidiabetic effects of Carassius auratus complex formula in high fat diet combined streptozotocin –induced diabetic mice. Evidence-Based Complementary and Alternative Medicine.

27. Zhang Y (2018) Preparation and characterization of D. opposita Thunb polysaccharide-zinc inclusion complex and evaluation of anti-diabetic activities. International Journal of Biological Macromolecules 121: 1029-1036.

28. Kubo K (2012) Pueraaria flos alleviates metabolic diseases in Western diet-loaded, spontaneously obese type 2 diabetic model mice. Journal of Natural Medicines 66: 622-630.

29. Chen XF (2018) Effect of pueraolin in promoting fatty acid oxidation by increasing mitochondrial oxidative capacity and biogenesis in skeletal muscle in diabetic rats. Nutrition and Diabetes 8: 1.

30. Dong S (2018) Upregulation of UDP-Glucuronosyltransferases 1a1 and 1a7 are spontaneously obese type 2 diabetic model mice. Molecules 23: 1487.

31. Gao K (2018) Effects of Ojiam mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology. Pharmacological Research 130: 93-109.

32. Wang W (2018) Metabolomics-based evidence of the hypoglycemic effect of Ge-Gen-Jiao-Tai-Wan in type 2 diabetic rats via UHPLC-QTOF/MS analysis. Journal of Ethnopharmacology 219: 299-318.

33. Zhao, J, Li, Y, Sun, M, Xin, L, Wang, T, Wei, L, Yu, C, Liu, M, Ni, Y, Lu, R, Bao, T. (2019) The Chinese herbal formula Shenzhu Tiaopi granule results in metabolic improvement in type 2 diabetic rats by modulating the gut microbiota. Evidence-Based Complementary and Alternative Medicine 2019. [Crossref]

34. Gross JL, de Azevedo MJ, Silveiro SP, Canihi LH, Caramori ML, et al. (2004) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28: 164-76. [Crossref]

35. Wang ZS (2015) Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrology 16: 44. [Crossref]

36. Gui D (2013) Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic nephropathy in rats. Complementary and Alternative Medicine 20: 1574-1582.

37. Tripathi YB, Shukla R, Pandey N, Panley V, Kumar M, et al. (2017) An extract of Pueraaria tuberosa tubers attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in the kidney of diabetic rats. Journal of Diabetes 9: 123-132.

38. Rashmi S, Somanshu B, Tripathi YB (2018) Antioxidant and antiapoptotic effect of aqueous extract of Pueraaria tuberosa (roxb. ex wildd.) dc. on streptozotocin-induced diabetic nephropathy in rats. BMC Complementary and Alternative Medicine 18: 156.

39. Cherten, Z, Yuan, Z, Zou, X, Huang, W, Zhao, M, et al. (2016) Puerarin, isolated from Pueraaria lobata (Willd.), protects against diabetic nephropathy by attenuating oxidative stress. Gene 591: 411-416.

40. Chen Z, Yuan Y, Zou X, Hong M, Zhao M, et al. (2017) Radix Pueraia and Fructus Crataegi mixture inhibits renal injury in type 2 diabetes via decreasing of AKT/PI3K. BMC Complementary and Alternative Medicine 17: 454. [Crossref]

41. Nentwich MM (2015) Diabetic retinopathy-ocular complications of diabetes mellitus. World Journal of Diabetes 6: 489. [Crossref]

42. Jian W (2016) A combination of the main constituents of Fufang Xueshuantong Capsules shows protective effects against streptozotocin-induced retinal lesions in rats. Journal of Ethnopharmacology 182: 50-56. [Crossref]

43. Cai J, Boulton M (2002) The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 16: 242-266. [Crossref]

44. Li X, Cui, X, Yang, J, Yang, J, Sun, X, et al. (2013) Rhizome of Anemarrhena asphodeloides counteracts diabetic opthalmopathy progression in streptozotocin-induced diabetic rats. Phytotherapy Research 27: 1243-1256. [Crossref]

45. Zhang, Duzhen LI (2019) Puerarin prevents cataract development and progression in diabetic rats through Nrf2/HO-1 signaling. Molecular Medicine Reports 20:1017-1024. [Crossref]

46. Joshi M, Kotha SR, Malireddy S, Selvaraju V, Satoskar AR, et al. (2014) Conundrum of pathogenesis of diabetic cardiomyopathy: Role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria. Mol Cell Biochem 386: 233-249.

47. Chen W, Li YM, Yu MH (2010) Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation. J Diabetes Complications 4: 199-208.

48. Chen W (2012) The critical role of astragalus polysaccharides for the improvement of pparα-mediated lipotoxicity in diabetic cardiomyopathy. PLoS One 7: e45541.

49. Yu W, Zha W, Guo S, Cheng H, Wu J, et al. (2014) Flavonoid extract prevents myocardial apoptosis via attenuation oxidative stress in streptozotocin-induced diabetic mice. PLoS one 9: e98044. [Crossref]

50. Guo BQ (2018) Puerarin reduces ischemia/reperfusion-induced myocardial injury in diabetic rats via upregulation of vascular endothelial growth factor A/angiotsin-1 and suppression of apoptosis. Molecular Medicine Reports 17: 7421-7427.

51. Ott A, Stolz RP, Hofman A, van Harskamp F, Grobbee DE, et al. (1996) Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39: 1392-1397.

52. Liu Y, Liu W, Li J, Tang S, Wang M, et al. (2019) A polysaccharide extracted from Astragalus membranaceus residue improves cognitive dysfunction by altering gut microbiota in diabetic mice. Carbohydrate Polymers 205: 500-512. [Crossref]

53. Dan C (2016) Effects of Astragalus polysaccharides on memory impairment in a diabetic rat model. Neuropsychiatric Disease and Treatment 12: 1617.

J Transl Sci, 2020 doi: 10.15761/JTS.1000395 Volume 7: 15-16
61. Liu YW (2012) Total saponins from Rhizoma Anemarrhenae ameliorate diabetes-associated cognitive decline in rats: involvement of amyloid-beta decrease in brain. Journal of Ethnopharmacology 139: 194-200.

62. Chen MF (2012) Activation of imidazoline i-2 receptors by allantoin to increase glucose uptake into c2c12 cells. Hormone and Metabolic Research 44: 268-272.

63. Zhang D, Gao, X, Wang, Q, Qin, M, Liu, K, Huang, F, Liu, B (2013) Kakkalide ameliorates endothelial insulin resistance by suppressing reactive oxygen species-associated inflammation. Journal of Diabetes 5: 13-24.

64. Zhang R, Qin X, Zhang T, Li Q, Zhang J, et al. (2018) Astragalus polysaccharide improves insulin sensitivity via AMPK activation in 3T3-L1 adipocytes. Molecules 23: 2711.

65. Jin D (2016) Schisandra polysaccharide increased glucose consumption by up-regulating the expression of GLUT-4. International Journal of Biological Macromolecules 87: 555-562.

66. Lee, B, H, Hsu, W, H, Pan, T. M. (2011) Inhibitory effects of dioscorea polysaccharide on TNF-α-induced insulin resistance in mouse FL388 cells. Journal of Agricultural and Food Chemistry 59: 5279-5285.

67. [Crossref]

68. Ke M (2012) The effect of astragalin on the VEGF production of cultured Müller cells under high glucose conditions. Bio-medical materials and engineering 22: 113-119. [Crossref]

69. Chen X (2018) Astragaloside IV ameliorates high glucose-induced renal tubular epithelial-mesenchymal transition by blocking mtorc1/p70s6k signaling in bk-2 cells. International Journal of Molecular Medicine 43: 709-716.

70. Sun S (2017) The effect of Astragalus polysaccharides on attenuation of diabetic cardiomyopathy through inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose stimulated H9C2 cells. BMC Complementary and Alternative Medicine 17: 310.

71. Lian D (2019) Puerarin inhibits hyperglycemia-induced inter-endothelial junctional disruption through suppressing endothelial Nlrp3 inflammasome activation via ROS-dependent oxidative pathway. Phytomedicine 55: 310-319.

72. Fong CC (2011) Danshen-Gegen decoction exerts proliferative effect on rat cardiac myoblasts H9c2 via MAPK and insulin pathways. Journal of Ethnopharmacology 138: 60-66.

73. Vinik AI (2003) Diabetic autonomic neuropathy. Diabetes Care 26: 1553-1579.

74. Xue B (2017) Puerarin may protect against Schwann cell damage induced by glucose fluctuation. Journal of Natural Medicines 71: 472-481.

75. Zhang MY (2018) Sarsasapogenin suppresses Aβ overproduction induced by high glucose in HT-22 cells. Naunyn-Schmiedeberg's Archives of Pharmacology 391: 159-168.

76. Leng B, Tang F, Lu M, Zhang Z, Wang H, et al. (2018) Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway. Life Sciences 209: 111-121.

77. Huang F (2012) Puerarin attenuates endothelial insulin resistance through inhibition of inflammatory response in an Ikkβ/Irs-1-dependent manner. Biochimie 94: 1143-1150.

78. Sun J (2019) APS could potentially activate hepatic insulin signaling in HFD-induced IR mice. Journal of Molecular Endocrinology 63: 77-91. [Crossref]

79. Zou F, Mao XQ, Wang N, LiuJ, Ou-Yang JP, et al. (2009) Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPK. Acta Pharmacologica Sinica 30: 1607. [Crossref]

80. Liu Q, Liu S, Gao L, Sun S, Huan Y, et al. (2017) Anti-diabetic effects and mechanisms of action of a Chinese herbal medicine preparation QJR-in vitro and in diabetic KKAY mice. Acta Pharmacologica Sinica 37: 461-469. [Crossref]

81. Cao H (2017) Immune and metabolic regulation mechanism of Dangguihuang decoction against insulin resistance and hepatic steatosis. Frontiers in Pharmacology 8: 445. [Crossref]

82. Jung DY (2017) Antiobesity effect of gomisin N via activation of AMP-activated protein kinase. Biochemical and Biophysical Research Communications 494: 587-593. [Crossref]

83. Nagappan A (2018) Protective effects of gomisin against hepatic cannabinoid type 1 receptor-induced insulin resistance and glucose homeostasis. International Journal of Molecular Sciences 19: 968.

84. Park S (2009) Huang-Lian-Jie-Du-Tang supplemented with Schisandra chinensis Baill. and Polygonatum odoratum Druce improved glucose tolerance by potentiating insulino-motrophic actions in ilets in 90% pancreatectomized diabetic rats. Bioscience, Biotechnology, and Biochemistry 73: 2384-2392.

85. Han J (2015) Rhizoma Anemarrhenae extract ameliorates hyperglycemia and insulin resistance via activation of AMP-activated protein kinase in diabetic rodents. Journal of Ethnopharmacology 172: 368-376.

86. Sun R (2019) Anti-diabetic potential of Pueraria lobata root extract through promoting insulin signaling by PTP1B inhibition. Bioorganic Chemistry 87: 12-15.

87. Chen X (2018) Puerarin acts on the skeletal muscle to improve insulin sensitivity in diabetic rats involving α1-opioid receptor. European Journal of Pharmacology 818: 115-123. [Crossref]

88. Yeo, J, Kang, Y, M, Cho, S, I, Jung, M, H. (2011) Effects of a multi-herbal extract on type 2 diabetes. Chinese Medicine 6: 10. [Crossref]

89. Lu J, Peng J, Xiang M, He, L, Wang, D, et al. (2018) Trichosanthes kirilowii lectin alleviates diabetic nephropathy by inhibiting the LOX1/NFκb/caspase-9 signaling pathway. Bioresource Reports 38.

90. Chen W (2015) Astragalus polysaccharides repress myocardial lipotoxicity in a PPARα-dependent manner in vitro and in vivo in mice. Journal of Diabetes and its Complications 29: 164-175.

91. Tian J (2018) Shengmai san alleviates diabetic cardiomyopathy through improvement of mitochondrial lipid metabolic disorder. Cellular Physiology and Biochemistry 50: 1726-1739.

92. Peng KY (2011) Hepatocyte growth factor has a role in the amelioration of diabetic vascular complications via autophagic clearance of advanced glycation end products: disposeS5e, an hgf inductor, as a potential botanical drug. Metabolism Clinical & Experimental 60: 888-892.

93. Zhao W (2019) Aqueous extract of Salvia miltiorrhiza Bunge-Radix Puerariae herb pair ameliorates diabetic vascular injury by inhibiting oxidative stress in streptozotocin-induced diabetic rats. Food and Chemical Toxicology 129: 97-107. [Crossref]

94. Liu J (2014) Application of temperature-correlated mobility theory for optimizing the MEKC separation of the main lignans from Schisandra Chinensis Fructus and its prescription Yuye Decoction. Electrophoresis 35: 2907-2914. [Crossref]

95. Chang YX (2015) The multi-targets integrated fingerprinting for screening anti-diabetic compounds from a Chinese medicine Inqi Jiangtang tablet. Journal of Ethnopharmacology 164: 210-222. [Crossref]

96. Deng W, Wang H, Wu B, Zhang X (2019) Selenium-layered nanoparticlest serving for oral delivery of phytomedicines with hypoglycemic activity to synergistically potentiate the anti-diabetic effect. Acta Pharmaceutica Sinica B 9: 74-86. [Crossref]

97. Lin A, Li J, Li D, Jin H, Liu Y, et al. (2019) Tissue distribution study of mangiferin after intragastric administration of mangiferin monomer, Rhizoma Anemarrhenae, and Rhizoma Anemarrhenae-Phellodendron decoctions in normal or type 2 diabetic rats by LC-MS/MS. Journal of Chromatography B 1122: 18-28. [Crossref]

98. Lin YS (2016) Synthesized peptides from yam dioscorin hydrolysis in silico exhibit dipeptidyl peptidase-IV inhibitory activities and oral glucose tolerance improvements in normal mice. Journal of Agricultural and Food Chemistry 64: 6451-6458. [Crossref]

99. Motomura K (2009) Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. Journal of Agricultural and Food Chemistry 57: 7666-7672. [Crossref]

100. Chao M (2009) Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients. Endocrine 36: 268-274. [Crossref]

101. Lien ASY (2016) Integrative traditional Chinese medicine therapy reduces the risk of diabetic ketoadioidosis in patients with type 1 diabetes mellitus. Journal of Ethnopharmacology 191: 324-330.

102. Lo HY (2017) Hypoglycemic effects of Trichosanthes kirilowii and its protein constituent in diabetic mice: the involvement of insulin receptor pathway. BMC Complementary and Alternative Medicine 17: 53. [Crossref]

Copyright: ©2020 Wan JH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

J Transl Sci, 2020
doi: 10.15761/JTS.1000395
Volume 7: 16-16